Axovant reports Phase II data for dementia candidate nelotanserin

Axovant Sciences Ltd. (NASDAQ:AXON) reported data from 27 evaluable patients with dementia with Lewy bodies (DLB) and Parkinson's disease dementia who were experiencing frequent and recurrent visual hallucinations in a Phase II trial evaluating nelotanserin. Compared to placebo, nelotanserin non-significantly improved Unified Parkinson's Disease Rating Scale (UPDRS) Part III motor scores by 3.12 points (unadjusted p=0.075) and Scale for the Assessment of Positive Symptoms-PD (SAPS-PD) score by 0.88 points (unadjusted p=0.519) from baseline to day 28. In a subgroup of patients with a baseline SAPS-PD score of >8 points (n=19), nelotanserin non-significantly improved SAPS-PD score by 1.21 points from baseline to day 28 vs. placebo (unadjusted p=0.531). Nelotanserin was generally well tolerated.

Patients in the double-blind, crossover, U.S. trial received placebo for four weeks or 40 mg nelotanserin for the first two weeks followed by 80 mg nelotanserin for two weeks, followed by a four-week washout period before switching treatments...